NASDAQ:GHRS GH Research Q3 2025 Earnings Results & Report $18.85 -1.17 (-5.84%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$18.32 -0.53 (-2.79%) As of 08:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. GH Research met analyst earnings expectations in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$0.23 versus the -$0.23 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 6, 2025TimeBefore Market OpensConference Call DateNovember 5, 2025Conference Call6:00 PM ET GH Research EPS ResultsActual EPS-$0.23Consensus EPS -$0.23Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersGH Research Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsGH Research's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(6-K) GH Research Q3 2025 Earnings FAQ Did GH Research beat earnings estimates for Q3 2025? GH Research (NASDAQ:GHRS) reported earnings of -$0.23 per share for Q3 2025, matching the consensus estimate of -$0.23. The report was announced on Thursday, November 6, 2025. When is GH Research's next earnings date? GH Research's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for GH Research on the company's earnings history page. GH Research Earnings HeadlinesGH Research to Present TRD and Bipolar Trial Data at ECNP 2026October 9, 2026 | tipranks.comGH Research PLC (NASDAQ:GHRS) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesOctober 3, 2026 | americanbankingnews.comElon's next millionaires start October 24?SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into millionaires. One welder's $10,000 stock package made him a millionaire on IPO day. Former Wall Street CEO Dylan Jovine says Elon Musk's next venture could outsize everything he's built before. It runs on an obscure AI firm Musk has relied on since 2012, supplying crucial technology to Tesla, Starlink and SpaceX.October 14 at 1:00 AM | Behind the Markets (Ad)GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion OpportunitiesSeptember 20, 2026 | seekingalpha.comGH Research Files Q2 2026 Results and Updates Corporate PresentationAugust 6, 2026 | tipranks.comGH Research Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 6, 2026 | globenewswire.comSee More GH Research Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like GH Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GH Research and other key companies, straight to your email. Email Address About GH ResearchGH Research (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company focused on developing novel treatments for psychiatric and neurological disorders. The company’s research centers on mebufotenin, also known as 5-MeO-DMT, a psychedelic compound being evaluated through proprietary formulations and delivery methods designed to produce rapid-acting therapeutic effects. GH Research’s lead investigational program, GH001, is an inhaled formulation of mebufotenin being studied for major depressive disorder, including treatment-resistant depression. The company is also developing additional mebufotenin-based programs, including formulations intended for alternative routes of administration. These products remain investigational, and GH Research does not currently market an approved therapy. Headquartered in Dublin, Ireland, GH Research conducts clinical development activities internationally through studies involving patients in multiple regions. The company’s programs are focused on addressing psychiatric conditions for which existing treatments may have limited effectiveness or a delayed onset of action.View GH Research ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Tax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
